Prediction of toxicity but not of clinical course by determining carboplatin exposure in patients with epithelial ovarian cancer treated with a combination of carboplatin and cisplatin

International Journal of Oncology

Volumn 13, Issue 5, 1998, Pages 1023-1030

  Obermair, Andreas ^a   Speiser, Paul ^a   Thoma, Martin ^a   Kaider, Alexandra ^a   Salzer, Heinz ^b   Dittrich, Christian ^c   Sevelda, Paul ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b WILHELMINEN HOSPITAL   (Austria)

^c KAISER FRANZ JOSEF HOSPITAL   (Austria)

Author keywords

Area under thecurve; Carboplatin; Epithelial ovarian cancer; Toxicity

Indexed keywords

CARBOPLATIN; CISPLATIN; ONDANSETRON;

AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CREATININE CLEARANCE; DISEASE COURSE; DOSE RESPONSE; FEMALE; GRANULOCYTOPENIA; HISTOPATHOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; OTOTOXICITY; OVARY CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; THROMBOCYTOPENIA;

EID: 0031792514     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.5.1023     Document Type: Article

References (36)

1. Alberts DS, Green S, Hannigan EV, OToole R, Stock-Novack D, Anderson P, Surwit EA, Malvlya VK, Nahhas WA and Jolies CJ: Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 10: 706-717, 1992.
2. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MJ and Harrap KR: Early clinical studies with cisdiamine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 9: 140-147, 1982.
3. Egorin MJ, van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW and Aisner J: Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato) platinum in patients with impaired renal function. Cancer Res 44: 5432-5438, 1984.
4. Hannigan EV, Green S, Alberts DS, O'Toole R and Surwit E: Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer. Oncology 50 (Suppl 2): 2-9, 1993.
5. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME and Wiltshaw E: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756, 1989.
6. Levin L and Hryniuk WM: Dose intensity analysis of chemo-therapy regimens in ovarian carcinoma. J Clin Oncol 5: 756-767, 1987.
7. Dittrich C, Sevelda P, Baur M, Marth C, Hudec M, Vavra N, Grunt T, Fazeny B and Salzer H: In vitro and in vivo evaluation of the combination of cisplatin and its analogue carboplatin for platinum dose intensification in ovarian carcinoma. Cancer 71: 3082-3090, 1993.
8. Trump DL, Grem JL, Tutsch KD, Willsonm JKV, Simon KJ, Alberti D, Storer B and Tormey DC: Atinum analogue combination chemotherapy: cisplatin and carboplatin - a phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion. J Clin Oncol 5: 1281-1289, 1987.
9. Adams M, Kerby IJ, Rocker I, Evans A, Johansen K and Franks CRA: Comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group. Acta Oncol 28: 57-60, 1989.
10. Wiltshaw E: Ovarian cancer trials at the Royal Marsden. Cancer Treat Rev 12 (Suppl A): 67-71, 1985.
11. Gershenson DM, Morris M, Burke TW, Levenback C, Kavanagh JJ, Fromm GL, Silva EG, Warner D and Wharton JT: Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer. Gynecol Oncol 58: 349-355, 1995.
12. Egorin MJ, Reyno LM, Canetta RM, Jodrell DI, Swenerton KD, Pater JL, Burroughs JN, Novak MJ and Sridhara R: Modelling toxicity and response in carboplatin-based combination chemotherapy. Semin Oncol 21 (Suppl 12): 7-19, 1994.
13. Reyno LM, Egorin MJ, Canetta RM, Jodrell DI, Swenerton KD, Pater JL, Burroughs JN, Novak MJ and Sridhara R: Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer. J Clin Oncol 11: 1156-1164, 1993.
14. Serov SF, Scully RE and Sarbin LH: International histological classification of tumors. WHO, Geneva, 1973.
15. International Federation of Gynecology and Obstetrics (FIGO): Changes in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 156: 263-264, 1987.
16. Day TG, Gallager HS and Rutledge FN: Epithelial carcinoma of the ovary: the prognostic importance of histologic grade. Natl Cancer Inst Monogr 42: 15-21, 1975.
17. Miller AB, Hoogstraten B, Staqquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
18. Grem J, O'Dwyer P, Elson P, Simon N, Trump D, Frontiera M, Falkson G and Vogl S: Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study. J Clin Oncol 9: 1793-1800, 1991.
19. Dixon WJ, Brown MB, Engelman L and Jennrich RI: BMDP statistical software manual. University of California Press, Berkeley, 1990.
20. Hosmer DJ and Lemeshow S: Applied logistic regression. Wiley, New York, 1989.
21. Campbell MJ and Machin D: Medical statistics - a commonsense approach. John Wiley & Sons, Chichester, 1995.
22. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Amer Statist Assn 53:457-481, 1985.
23. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170, 1966.
24. Cox DR: Regression models and life tables. J R Stat Soc Ser B Method 34: 187-220, 1972.
25. Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlow JL, Tan S and Wiltshaw E: Relationship between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10:520-528, 1992.
26. Daugaard G, Rossing N and Rørth M: Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother Pharmacol 21: 163-167, 1988.
27. Segelov E, Stuart-Harris R, Bell D, Tattersall M, Hutton-Potts J and Friedlander M: A phase II study of carboplatin and cisplatin in advanced ovarian cancer. Eur J Gynecol Oncol 15: 277-282, 1994.
28. Teeling M, Hayes Y, Fitzmaurice B, McGing P and Carney DN: Carboplatin/cyclophosphamide combination chemotherapy for advanced epithelial ovarian cancer. Semin Oncol 19 (Suppl 2): 102-106, 1992.
29. Bishop JF: Current experience with high-dose carboplatin therapy. Semin Oncol 19 (Suppl 2): 150-154, 1992.
30. Fenelly D, Wasserheit C, Schneider J, Hakes T, Reich L, Curtin J, Yao TJ, Markman M, Norton L and Crown J: Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial. Cancer Res 54: 6137-6142, 1994.
31. Fanning J and Hilgers RD: High-dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer. Gynecol Oncol 51: 182-186, 1993.
32. Ozols RF: Carboplatin and paclitaxel (Taxol®) for the treatment of advanced ovarian cancer. Int J Gynecol Cancer 4 (Suppl 1): 13-17, 1994.
33. Egorin MJ, van Echo CA, Olman EA, Whitacre MY, Forrest A and Aisner J: Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diaminecyclobutane-dicarboxylatoplatinum. Cancer Res 45: 6502-6506, 1985.
34. Hecquet B, Caty A, Fournier C, Lefebrvre JL and Adenis L: Comparison of platinum concentrations in human head and neck tumours following administration of carboplatin, iproplatin or cisplatin. Bull Cancer 74:433-436, 1987.
35. Young RC, von Hoff DD, Gormley P, Makuch R, Cassidy J, Howser D and Bull J: Cis-dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer. Cancer Treat Rep 63: 1539-1544, 1979.
36. Reece PA, Stafford I, Russel J and Gill PG: Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatin. J Clin Oncol 4: 1392-1398, 1986.